GlassScriptPhysician profile
Houshang Moayeri
NPI 1508814716
$1,672.12
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $319 · 2021: $55.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $157.20 | 2019-2020 | |
| Genentech USA, INC. | $132.81 | 2019 | |
| Janssen Biotech, INC. | $127.73 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $110.69 | 2019-2020 | |
| Lilly USA, LLC | $84.54 | 2019-2020 | |
| Amgen INC. | $74.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $70.52 | 2019 | |
| Exelixis INC. | $64.68 | 2019 | |
| Foundation Medicine, INC. | $61.02 | 2020 | |
| Eisai INC. | $61.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.38 | 2019 | |
| Celgene Corporation | $47.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.56 | 2019 | |
| Abbvie INC. | $39.49 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $35.97 | 2019 | |
| Octapharma USA, INC. | $31.25 | 2020 | |
| Tersera Therapeutics LLC | $29.54 | 2019 | |
| Pfizer INC. | $28.19 | 2019 | |
| Partner Therapeutics, INC. | $27.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.66 | 2019 | |
| Seagen INC. | $22.77 | 2019 | |
| Gilead Sciences, INC. | $22.62 | 2019 | |
| Dendreon Pharmaceuticals LLC | $21.69 | 2020 | |
| Amag Pharmaceuticals, INC. | $21.43 | 2019 | |
| Csl Behring | $18.32 | 2019 | |
| Astellas Pharma US INC | $18.01 | 2019 | |
| Dova Pharmaceuticals | $17.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.98 | 2019 | |
| Shionogi INC | $16.80 | 2019 | |
| Array Biopharma INC | $15.05 | 2020 | |
| Clovis Oncology, INC. | $13.54 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.26 | 2019 | |
| Genzyme Corporation | $12.44 | 2019 | |
| Incyte Corporation | $11.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Houshang Moayeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.